Palatin Technologies Presents At The 9th European Society For Sexual Medicine (ESSM) Congress

Main Category: Erectile Dysfunction / Premature Ejaculation
Also Included In: Men's health;  Clinical Trials / Drug Trials;  Conferences
Article Date: 06 Dec 2006 - 0:00 PDT

email to a friend   printer friendly   opinions  

Palatin Technologies, Inc. (Amex: PTN) today announced it presented results from two Phase 2B trials evaluating bremelanotide for the treatment of male erectile dysfunction (ED) at the 9th European Society for Sexual Medicine (ESSM) Congress at the Hofburg Convention Center, Vienna on December 5, 2006. This presentation received "The European Society for Sexual Medicine 2006 Award for Best Presentation on Male Sexual Dysfunction (Clinical)."

The slide presentation will be available later today on the company's website at http://www.palatin.com.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company primarily focused on discovering and developing targeted, receptor-specific small- molecule and peptide therapeutics. The Company's drug development pipeline includes primarily melanocortin-based therapeutics. The Company's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. To date, the Company has formed partnerships with Tyco Healthcare Mallinckrodt and King Pharmaceuticals. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Forward-looking Statements

Statements about the Company's future expectations, including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to the Company's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre- clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R), ability to protect its intellectual property, and other factors discussed in the Company's periodic filings with the Securities and Exchange Commission. The Company is not responsible for updating for events that occur after the date of this press release.

Palatin Technologies, Inc.
http://www.palatin.com

• Additional
• References
• Citations